Left Menu
Development News Edition

Fonterra lends high tech bioprocessing equipment to NZ Covid-19 Vaccine Corp

CVC utilises a well-established technology originally developed at Massey University which enables the efficient production of tiny biobeads that are coated in any protein or polypeptide that is chosen.

Devdiscourse News Desk | Wellington | Updated: 02-09-2020 08:58 IST | Created: 02-09-2020 08:58 IST
Fonterra lends high tech bioprocessing equipment to NZ Covid-19 Vaccine Corp
Fonterra’s equipment is being used to break open the bacteria in which CVC’s vaccine biobeads are made. Image Credit: Wikimedia

Fonterra is lending its high tech bioprocessing equipment to New Zealand Covid-19 Vaccine Corporation, to help speed up the company's efforts towards producing a vaccine in New Zealand.

"As CVC progresses its unique vaccine candidate, we require the use of many types of specialised equipment some of which can be challenging to get access to. We are therefore very pleased to be able to access Fonterra's resources and apply sophisticated equipment to the manufacture of our vaccine candidate," says CVC chief executive Dr Robert Feldman.

CVC utilises a well-established technology originally developed at Massey University which enables the efficient production of tiny biobeads that are coated in any protein or polypeptide that is chosen.

CVC is coating these biobeads in carefully chosen components from the SARS-Cov-2 virus. The biobeads and coating are simultaneously manufactured inside bacteria which is an efficient method of production.

Fonterra's equipment is being used to break open the bacteria in which CVC's vaccine biobeads are made. "Once the biobeads are released, we remove contaminating bacterial residues and end up with a pure vaccine preparation ready for injection," says CVC chief operating officer Dr Andy Herbert.

Fonterra Director of Category, Strategy and Innovation, Mark Piper says it's good to be able to help out in a small way.

"We always like to help out where we can, so when the team came and asked if they could borrow a homogeniser from our Research centre, we quickly worked to free up the equipment for CVC. This could be good not just for CVC but good for New Zealand and the rest of the world."

The partnership comes following the Government's announcement last week, that it's contributing hundreds of millions of dollars to onshore and offshore efforts to produce and obtain a Covid-19 vaccine for New Zealanders and its Pacific partners.

To date, CVC has raised a million dollars in private company funding, following the initial $488,000 interim funding it received from the Ministry of Business, Innovation and Employment Covid-19 Innovation Acceleration Fund.

"CVC is excited to hear about last week's Government announcement and fully supports a strategy to bring a safe and effective vaccine to New Zealand. CVC's candidate uses an approach that is different from other candidates being developed around the world that it believes will generate a strong and broad immune response while being efficient to manufacture. We hope to be an integral part of our Government's COVID-19 vaccine strategy," explains Dr Robert Feldman.

The company estimates its first clinical trials will conclude in early 2022 and would cost around $8 million to complete. It's already in partnership with the University of Auckland, Callaghan Innovation, and Ardigen.

CVC is made up of a group of lifelong biotech experts including Dr Robert Feldman who is a serial biotech entrepreneur and medical doctor with vaccine experience, Dr Andy Herbert, a pharmaceutical development and manufacturing expert, Tara Creaven-Capasso, a regulatory, quality and biotech expert with extensive international experience and Helen Teale, a global clinical trial management expert.

The company is chaired by Jeff Douglas, managing director of Douglas Pharmaceuticals.


TRENDING

OPINION / BLOG / INTERVIEW

Post-COVID-19 Nigeria needs a robust Health Management Information System to handle high disease burden

Nigeria is among a few countries that conceptualised a health management information system HMIS in the early 90s but implementation has been a challenge till date. Besides COVID-19, the country has a huge burden of communicable and non-com...

Morocco COVID-19 response: A fragile health system and the deteriorating situation

Learning from its European neighbors, Morocco imposed drastic measures from the initial stages of the COVID-19 outbreak to try to contain its spread. The strategy worked for a few months but the cases have surged after mid-June. In this sit...

COVID-19: Argentina’s health system inefficiencies exaggerate flaws of health information system

You can recover from a drop in the GDP, but you cant recover from death, was the straightforward mindset of Argentinas President Alberto Fernndez and defined the countrys response to COVID-19. The South American nation imposed a strict...

Rwanda’s COVID-19 response commendable but health information system needs improvement

Rwanda is consistently working to improve its health information system from many years. However, it is primarily dependent on the collection and reporting of health data on a monthly basis. Besides, evaluation studies on Rwandas HIS publis...

Videos

Latest News

Israel tightens second lockdown as virus cases soar

Israel on Thursday moved to further tighten its second countrywide lockdown as coronavirus cases continued to soar. The Cabinet voted to close all nonessential businesses, including open-air markets. Prayers and political demonstrations wou...

Data breach at software provider to local governments

A major provider of software services to local governments and schools across the United States, Tyler Technologies, told customers Wednesday that an unknown intruder broke into its phone and information technology systems. It could not imm...

UK may inject volunteers with coronavirus for vaccine trials: Report

Scientists in the UK are moving towards what are being referred to as challenge trials, which will involve healthy volunteers being deliberately infected with the novel coronavirus to test whether a vaccine offers any protection, according ...

Slovakia reports record daily COVID-19 tally for a second day

Slovakia, which has one of Europes lowest death tolls from the novel coronavirus, reported its highest daily tally of COVID-19 cases for a second day in a row on Thursday, registering 360 positive tests in the previous day.Since the start o...

Give Feedback